BioLargo Inc. reports Q3 revenue of $1.21 million and cash balance of $4.5 million

Reuters11-17

BioLargo Inc. reports Q3 revenue of $1.21 million and cash balance of $4.5 million

BioLargo Inc. reported third-quarter 2025 revenues of $1.2 million and year-to-date revenues of $7.3 million. The company ended the quarter with a cash balance of $4.5 million, total assets of $9.2 million, total liabilities of $5.9 million, and stockholders' equity of $3.3 million. The year-over-year revenue decline was mainly due to reduced sales of the Pooph-branded pet odor product following the revocation of its license. BioLargo announced progress in commercialization efforts, with its wound care and surgical product lines nearing launch, advancements in PFAS treatment technology, and continued development of the Cellinity battery platform. The company stated it has no toxic debt and is pursuing a federal lawsuit related to the Pooph agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLargo Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102916) on November 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584610246?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584610246","market":"nz","top_or_hot":-1,"title":"BioLargo Inc. reports Q3 revenue of $1.21 million and cash balance of $4.5 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioLargo Inc. reports Q3 revenue of $1.21 million and cash balance of $4.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioLargo Inc. reported third-quarter 2025 revenues of $1.2 million and year-to-date revenues of $7.3 million. The company ended the quarter with a cash balance of $4.5 million, total assets of $9.2 million, total liabilities of $5.9 million, and stockholders' equity of $3.3 million. The year-over-year revenue decline was mainly due to reduced sales of the Pooph-branded pet odor product following the revocation of its license. BioLargo announced progress in commercialization efforts, with its wound care and surgical product lines nearing launch, advancements in PFAS treatment technology, and continued development of the Cellinity battery platform. The company stated it has no toxic debt and is pursuing a federal lawsuit related to the Pooph agreements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLargo Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102916) on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioLargo Inc. reports Q3 revenue of $1.21 million and cash balance of $4.5 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioLargo Inc. reports Q3 revenue of $1.21 million and cash balance of $4.5 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-17 16:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioLargo Inc. reports Q3 revenue of $1.21 million and cash balance of $4.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioLargo Inc. reported third-quarter 2025 revenues of $1.2 million and year-to-date revenues of $7.3 million. The company ended the quarter with a cash balance of $4.5 million, total assets of $9.2 million, total liabilities of $5.9 million, and stockholders' equity of $3.3 million. The year-over-year revenue decline was mainly due to reduced sales of the Pooph-branded pet odor product following the revocation of its license. BioLargo announced progress in commercialization efforts, with its wound care and surgical product lines nearing launch, advancements in PFAS treatment technology, and continued development of the Cellinity battery platform. The company stated it has no toxic debt and is pursuing a federal lawsuit related to the Pooph agreements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLargo Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102916) on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4109","symbol_name":"特种化学制品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL4JP6pv:1","article_id":"2584610246","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584610246","pubTimestamp":1763366439,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioLargo Inc. reported third-quarter 2025 revenues of $1.2 million and year-to-date revenues of $7.3 million. The company ended the quarter with a cash balance of $4.5 million, total assets of $9.2 million, total liabilities of $5.9 million, and stockholders' equity of $3.3 million. The year-over-year revenue decline was mainly due to reduced sales of the Pooph-branded pet odor product following the revocation of its license. BioLargo announced progress in commercialization efforts, with its wound care and surgical product lines nearing launch, advancements in PFAS treatment technology, and continued development of the Cellinity battery platform. The company stated it has no toxic debt and is pursuing a federal lawsuit related to the Pooph agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4109":"特种化学制品","BLGO":"BioLargo, Inc."},"translate_title":"BioLargo Inc.报告第三季度收入为121万美元，现金余额为450万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLGO":0.9},"content_text":"BioLargo Inc. reports Q3 revenue of $1.21 million and cash balance of $4.5 million\n    \n\n        BioLargo Inc. reported third-quarter 2025 revenues of $1.2 million and year-to-date revenues of $7.3 million. The company ended the quarter with a cash balance of $4.5 million, total assets of $9.2 million, total liabilities of $5.9 million, and stockholders' equity of $3.3 million. The year-over-year revenue decline was mainly due to reduced sales of the Pooph-branded pet odor product following the revocation of its license. BioLargo announced progress in commercialization efforts, with its wound care and surgical product lines nearing launch, advancements in PFAS treatment technology, and continued development of the Cellinity battery platform. The company stated it has no toxic debt and is pursuing a federal lawsuit related to the Pooph agreements.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLargo Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102916) on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584610246","isCrawlerRequest":true}